Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  cladribine
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-22 of 22 for your search:
Start Over
German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003)
Phase: Phase IV
Type: Treatment
Status: Active
Age: 15 to 65
Sponsor: Other
Protocol IDs: GMALL01, NCT00198991
Therapy-Optimization Trial for the Treatment of Acute Myeloid Leukemias (AML) in Children and Adolescents
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 and under
Sponsor: Other
Protocol IDs: BfArM 4022064, DKH 50-2728, UCHM-AML-BFM-2004, UCHM-BfArM 4022064, UCHM-DKH 50-2728, EU-20723, AML-BFM 2004, NCT00111345
Cladribine Plus Pegylated Interpheron Alfa-2a in Systemic Mastocytosis
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: EC11-187, NCT01602939
Therapy Optimisation for the Treatment of Hairy Cell Leukemia
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 90
Sponsor: Other
Protocol IDs: NHL 3-2004, NCT02131753
Role of the Therapy Tailored to Risk Factors in Treating Adult Patients (=60) With Acute Myeloid Leukemia
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 60
Sponsor: Other
Protocol IDs: PALG-AML2012, NCT02072811
Trial to Test the Effects of Adding 1 of 2 New Treatment Agents to Commonly Used Chemotherapy Combinations
Phase: Phase III
Type: Biomarker/Laboratory analysis, Tissue collection/Repository, Treatment
Status: Approved-not yet active
Age: 60 and over
Sponsor: Other
Protocol IDs: AML18, NCT02272478
Idarubicin Plus Cytarabine (IA) vs IA Plus Cladribine (IAC) as Induction Regimen to Treat Initially Diagnosed Acute Myeloid Leukemia (AML)
Phase: Phase III
Type: Treatment
Status: Approved-not yet active
Age: 18 to 60
Sponsor: Other
Protocol IDs: SZ3202, NCT02323022
Low Dose CdA Combined With Valproic Acid (VPA) in Previously Treated B-cell Chronic Lymphocytic Leukemia(B-CLL)
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: VPA-CdA, NCT01295593
Bortezomib (VELCADE), Cladribine and Rituximab (VCR) in Mantle Cell Lymphoma (PSHCI 10-011)
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: PSHCI 10-011, NCT01439750
Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 2734.00, NCI-2013-02465, 2734, P30CA015704, NCT02044796
Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia
Phase: Phase II, Phase I
Type: Treatment
Status: Approved-not yet active
Age: 18 to 70
Sponsor: Other
Protocol IDs: 15-x090, NCT02416908
Cladribine, Cytarabine and Idarubicin in Patients With Relapsed Acute Myelocytic Leukemia (AML)
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CAI, NCT00126321
2CDA With Rituximab in Hairy Cell Leukemia
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2004-0223, NCI-2012-01394, NCT00412594
Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 090005, 09-C-0005, NCT00923013
R-2cda and Prolongation of Therapy With Rituximab Alone in Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: IEO S523/110, 2010-018519-14, NCT01446900
Trial of Cladribine, Cytarabine, Mitoxantrone, Filgrastim (CLAG-M) in Relapsed Acute Lymphoblastic Leukemia
Phase: Phase II
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: L-10,442, NCT01513603
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Phase: Phase II
Type: Treatment
Status: Active
Age: 60 and over
Sponsor: Other
Protocol IDs: 2011-0987, NCI-2012-00145, NCT01515527
4-Arm Phase II Study of SGI-110 in Elderly Acute Myeloid Leukemia (AML)
Phase: Phase II
Type: Treatment
Status: Active
Age: Over 70
Sponsor: Other
Protocol IDs: 2013-0843, NCI-2014-00981, NCT02096055
Allogeneic Transplantation Using Timed Sequential Busulfan, Cladribine, and Fludarabine Conditioning in Patients With Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS)
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 2 to 70
Sponsor: Other
Protocol IDs: 2014-0431, NCI-2014-02324, NCT02250937
Nonmyeloablative Allogeneic Transplant
Phase: No phase specified
Type: Treatment
Status: Active
Age: 18 to 72
Sponsor: Other
Protocol IDs: IRB#13-6255, NCT01272817
Unrelated Donor Stem Cell Transplantation
Phase: No phase specified
Type: Treatment
Status: Active
Age: 18 to 69
Sponsor: Other
Protocol IDs: SIRB#13-6190, NCT01364363
Start Over